KRAS and neoplasm: Here we performed a comprehensive pan-cancer genomic analysis to identify the incidence of KRAS alterations across 24 tumor types, the distribution of KRAS alterations inclusive of and beyond G12C. We evaluated the genomic co-alteration landscapes and immune biomarker patterns in association with different KRAS mutations in terms of tumor mutational burden (TMB), PD-L1 expression, co-alterations, and mutational signatures that may modulate response to KRAS inhibitors, immune checkpoint inhibitors (ICI) or other therapies.